Drugs / CFG920
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01647789 | Dec 2012 → Feb 2016 | prostate cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04060394 | Sep 2019 → Dec 2023 | castration-resistant prostate carcinoma | Laekna Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT03843918 | Apr 2019 → Oct 2023 | metastatic prostate carcinoma | Laekna Limited | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CFG920 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01647789 ↗ |
| Known as | LAE001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03843918 ↗ |
| Action | Inhibit | “CFG920, a new CYP17 inhibitor” NCT01647789 ↗ |
| Modality | Small molecule | — CHEMBL4297485 ↗ |
| Route | Oral | “LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject.” NCT03843918 ↗ |